Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

The FDA has issued a warning as fake Ozempic have started circulating amid a recent trend seeing people using the diabetes ...

Dr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's popular weight-loss ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Older adults and women using Wegovy for obesity management may be more likely to lose lean mass, although increasing protein intake may help protect against lean mass loss, according to a speaker.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to go somewhere ...